Shown solid blue (Tier 1) on the CMS 2025 OPO Tier Status map based on 2023 performance data; OPO name and code MWOB confirmed in the document's OPO code table.
This OPO is graded Tier 1 (2025 (data year 2023)) under the CMS Conditions for Coverage outcome measures. Tier 1 is the top-performing band, automatically recertified.
OPOs hold board seats and reported financial stakes in tissue processors (per reform-group analysis of OPO 990s)
AlloSource board (executives from Donor Alliance, Iowa Donor Network, Mid-America Transplant, ConnectLife, Gift of Hope); MTF Biologics board (Midwest Transplant Network, LifeShare of Oklahoma, New Jersey Sharing Network)
A published analysis by Organ Donation Reform (costlyeffects.organdonationreform.org), citing the OPOs' own IRS Form 990 filings on ProPublica, states that executives from five named OPOs sit on AlloSource's board and that these OPOs hold ownership stakes in AlloSource ranging from $8 million to $26.4 million, and that executives from three additional named OPOs sit on the MTF Biologics board. This is an advocacy-group compilation derived from public 990 data, not a government finding; the underlying per-OPO 990 figures should be independently confirmed.
Reported OPO conflicts of interest concentrated in outside employment and outside board memberships, 2015-2023
LifeCenter Organ Donor Network; LifeShare Network; Midwest Transplant Network; Donor Alliance; Gift of Life Donor Program (and other surveyed OPOs)
The Senate Finance Committee 'Operation Transplant' report tabulated conflicts OPOs reported for 2015-2023, dominated by outside-employment and outside-board-membership conflicts: e.g., LifeCenter reported 53 outside-employment conflicts plus 18 financial conflicts; Midwest Transplant Network 20 outside-employment and 2 board conflicts; LifeShare 22 outside-employment and 8 board conflicts; Donor Alliance 7 outside-employment and 8 board conflicts; Gift of Life Donor Program 8 outside-employment, 7 board-service, and 5 financial conflicts. The report criticized the disclosures as vague and inconsistently reviewed.
Every item is institution-level public record, source-linked; no patient, donor, or family is named. A Tier or finding here repeats the government's own assessment of an organization holding a public monopoly. Back to OrganWatch.